Beam Therapeutics Inc. $BEAM Shares Sold by Liontrust Investment Partners LLP

Liontrust Investment Partners LLP decreased its stake in Beam Therapeutics Inc. (NASDAQ:BEAM) by 52.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 80,764 shares of the company’s stock after selling 89,640 shares during the quarter. Liontrust Investment Partners LLP’s holdings in Beam Therapeutics were worth $1,925,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in Beam Therapeutics by 139.4% during the fourth quarter. SG Americas Securities LLC now owns 103,469 shares of the company’s stock valued at $2,868,000 after buying an additional 60,249 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in shares of Beam Therapeutics in the fourth quarter worth approximately $2,130,000. Baillie Gifford & Co. increased its position in shares of Beam Therapeutics by 39.8% in the fourth quarter. Baillie Gifford & Co. now owns 416,224 shares of the company’s stock worth $11,538,000 after acquiring an additional 118,421 shares in the last quarter. Canal Insurance CO acquired a new stake in shares of Beam Therapeutics during the first quarter valued at approximately $953,000. Finally, Ishara Investments LP acquired a new stake in shares of Beam Therapeutics during the fourth quarter valued at approximately $1,386,000. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Insider Activity at Beam Therapeutics

In related news, insider Fmr Llc sold 251,488 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the transaction, the insider owned 854,583 shares of the company’s stock, valued at approximately $30,132,596.58. This trade represents a 22.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Amy Simon sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $25.74, for a total transaction of $429,008.58. Following the transaction, the insider directly owned 85,696 shares in the company, valued at approximately $2,205,815.04. The trade was a 16.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 301,527 shares of company stock valued at $10,468,500. 3.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on BEAM shares. Sanford C. Bernstein decreased their price objective on shares of Beam Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Beam Therapeutics in a research note on Tuesday, July 7th. Tudor Pickering set a $39.00 target price on shares of Beam Therapeutics in a research note on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Friday, July 17th. Finally, Bank of America reaffirmed a “buy” rating and issued a $47.00 target price on shares of Beam Therapeutics in a research report on Wednesday, July 8th. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Beam Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.85.

Beam Therapeutics Stock Performance

Shares of NASDAQ BEAM opened at $25.52 on Friday. The business’s 50-day moving average price is $31.01 and its two-hundred day moving average price is $29.19. The company has a debt-to-equity ratio of 0.09, a current ratio of 16.99 and a quick ratio of 16.99. Beam Therapeutics Inc. has a one year low of $15.60 and a one year high of $38.26. The company has a market capitalization of $2.63 billion, a P/E ratio of -37.53 and a beta of 2.18.

Beam Therapeutics (NASDAQ:BEAM) last issued its earnings results on Thursday, May 7th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.12. Beam Therapeutics had a negative return on equity of 29.00% and a negative net margin of 39.66%.The company had revenue of $31.74 million for the quarter, compared to analyst estimates of $10.98 million. During the same period in the prior year, the firm posted ($1.23) EPS. The business’s revenue was up 323.2% compared to the same quarter last year. Analysts anticipate that Beam Therapeutics Inc. will post -4.16 earnings per share for the current fiscal year.

Beam Therapeutics Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.